Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
